Equities analysts expect that Illumina, Inc. (NASDAQ:ILMN) will announce earnings of $1.18 per share for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Illumina’s earnings. The lowest EPS estimate is $1.16 and the highest is $1.20. Illumina posted earnings of $0.85 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 38.8%. The firm is scheduled to announce its next earnings results on Tuesday, January 30th.
On average, analysts expect that Illumina will report full-year earnings of $3.75 per share for the current financial year, with EPS estimates ranging from $3.73 to $3.78. For the next fiscal year, analysts forecast that the business will report earnings of $4.52 per share, with EPS estimates ranging from $4.20 to $4.82. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same quarter in the previous year, the business earned $0.97 EPS. The company’s quarterly revenue was up 17.6% on a year-over-year basis.
ILMN has been the topic of a number of analyst reports. Citigroup lifted their price objective on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Robert W. Baird raised shares of Illumina from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $184.00 to $228.00 in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target for the company in a research note on Friday, October 27th. Barclays boosted their price objective on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Finally, BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. Illumina currently has an average rating of “Buy” and an average target price of $201.98.
In other news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $212.55, for a total transaction of $4,251,000.00. Following the completion of the transaction, the director now owns 505,980 shares of the company’s stock, valued at $107,546,049. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total value of $29,323.35. The disclosure for this sale can be found here. Insiders sold a total of 166,150 shares of company stock worth $34,767,331 over the last 90 days. 0.89% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Advisory Services Network LLC boosted its position in shares of Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares in the last quarter. Penserra Capital Management LLC increased its stake in shares of Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares in the last quarter. Dupont Capital Management Corp bought a new stake in shares of Illumina in the 3rd quarter valued at $153,000. Paradigm Asset Management Co. LLC increased its stake in shares of Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares in the last quarter. Finally, Patten Group Inc. increased its stake in shares of Illumina by 71.1% in the 3rd quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after acquiring an additional 615 shares in the last quarter. 91.75% of the stock is owned by institutional investors and hedge funds.
Illumina (NASDAQ ILMN) traded up $2.98 on Friday, reaching $217.65. Illumina has a twelve month low of $121.47 and a twelve month high of $230.72. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market capitalization of $31,780.00, a price-to-earnings ratio of 63.64, a P/E/G ratio of 3.59 and a beta of 0.79.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.